MCID: ESP025
MIFTS: 42

Esophagus Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Esophagus Adenocarcinoma

MalaCards integrated aliases for Esophagus Adenocarcinoma:

Name: Esophagus Adenocarcinoma 12 15
Adenocarcinoma of Esophagus 12 44 73
Oesophageal Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4914
MeSH 44 C562730
NCIt 50 C4025
UMLS 73 C0279628

Summaries for Esophagus Adenocarcinoma

Disease Ontology : 12 An esophageal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Esophagus Adenocarcinoma, also known as adenocarcinoma of esophagus, is related to adenocarcinoma and barrett esophagus. An important gene associated with Esophagus Adenocarcinoma is HNF1A-AS1 (HNF1A Antisense RNA 1), and among its related pathways/superpathways are Gastric cancer and Colorectal Cancer Metastasis. The drugs Irinotecan and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and lung, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Related Diseases for Esophagus Adenocarcinoma

Diseases related to Esophagus Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 141)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 30.2 ERBB2 HNF1A-AS1 PTGS2 SMAD4 TP53
2 barrett esophagus 29.9 CDX2 ERBB2 PTGS2 TP53
3 squamous cell carcinoma 29.7 ERBB2 HNF1A-AS1 PTGS2 SMAD4 TP53
4 gastroesophageal reflux 29.7 CDX2 PTGS2 TP53
5 gastric adenocarcinoma 29.2 CDX2 ERBB2 PTGS2 SMAD4 TP53
6 esophageal cancer 29.0 CDX2 ERBB2 MIR21 PTGS2 SMAD4 TP53
7 lung cancer 28.7 AFAP1-AS1 ERBB2 HNF1A-AS1 MIR143 MIR145 MIR21
8 gastric cancer 28.2 AFAP1-AS1 CDX2 ERBB2 HNF1A-AS1 MIR143 MIR145
9 gastric papillary adenocarcinoma 10.3 ERBB2 TP53
10 pleomorphic adenoma carcinoma 10.3 ERBB2 TP53
11 non-proliferative fibrocystic change of the breast 10.3 ERBB2 TP53
12 uterine corpus serous adenocarcinoma 10.3 ERBB2 TP53
13 mutyh-associated polyposis 10.3 SMAD4 TP53
14 breast squamous cell carcinoma 10.3 ERBB2 TP53
15 uterine body mixed cancer 10.3 ERBB2 TP53
16 glioma susceptibility 1 10.2 ERBB2 TP53
17 microglandular adenosis 10.2 ERBB2 TP53
18 endocrine gland cancer 10.2 ERBB2 SMAD4 TP53
19 breast benign neoplasm 10.2 ERBB2 TP53
20 breast adenocarcinoma 10.2 ERBB2 SMAD4 TP53
21 thoracic benign neoplasm 10.2 ERBB2 TP53
22 nasal cavity adenocarcinoma 10.2 CDX2 TP53
23 uterine corpus cancer 10.1 ERBB2 TP53
24 vulva adenocarcinoma 10.1 CDX2 ERBB2
25 leukemia, chronic lymphocytic 2 10.1 MIR143 MIR145 TP53
26 biliary papillomatosis 10.1 CDX2 TP53
27 tongue squamous cell carcinoma 10.1 AFAP1-AS1 MIR21 TP53
28 hidradenocarcinoma 10.1 CDX2 ERBB2 TP53
29 biliary tract neoplasm 10.1 CDX2 SMAD4 TP53
30 endocervical adenocarcinoma 10.1 CDX2 TP53
31 protoplasmic astrocytoma 10.1 PTGS2 TP53
32 ovarian serous carcinoma 10.1 MIR143 MIR145 MIR21
33 fungal esophagitis 10.0 ATP12A ATP4A
34 diclofenac allergy 10.0 ATP12A ATP4A
35 gastroduodenal crohn's disease 10.0 ATP12A ATP4A
36 neonatal candidiasis 10.0 ATP12A ATP4A
37 squamous papillomatosis 10.0 ATP12A ATP4A
38 toxic megacolon 10.0 ATP12A ATP4A
39 aspiration pneumonitis 10.0 ATP12A ATP4A
40 gastrointestinal neuroendocrine benign tumor 10.0 ATP12A ATP4A
41 gastric antral vascular ectasia 10.0 ATP12A ATP4A
42 granulomatous gastritis 10.0 ATP12A ATP4A
43 esophageal candidiasis 10.0 ATP12A ATP4A
44 gastric neuroendocrine neoplasm 10.0 ATP12A ATP4A
45 acute laryngitis 10.0 ATP12A ATP4A
46 laryngitis 10.0 ATP12A ATP4A
47 duodenitis 10.0 ATP12A ATP4A
48 rumination disorder 10.0 ATP12A ATP4A
49 congenital disorder of deglycosylation 10.0 ATP12A ATP4A
50 bladder calculus 10.0 ATP12A ATP4A

Graphical network of the top 20 diseases related to Esophagus Adenocarcinoma:



Diseases related to Esophagus Adenocarcinoma

Symptoms & Phenotypes for Esophagus Adenocarcinoma

MGI Mouse Phenotypes related to Esophagus Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 ATP12A ATP4A CDX2 ERBB2 PTGS2 SMAD4
2 endocrine/exocrine gland MP:0005379 9.5 ATP4A CDO1 CDX2 ERBB2 PTGS2 SMAD4
3 neoplasm MP:0002006 9.1 ATP4A CDX2 ERBB2 PTGS2 SMAD4 TP53

Drugs & Therapeutics for Esophagus Adenocarcinoma

Drugs for Esophagus Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 188)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
2
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1 58-05-9 6006 143
3
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
4
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
5
Levoleucovorin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 68538-85-2
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
7
Camptothecin Experimental Phase 4,Phase 2,Phase 1 7689-03-4
8 Liver Extracts Phase 4,Phase 2,Phase 1
9 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
10 Antidotes Phase 4,Phase 2,Phase 3,Phase 1
11 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1
13 Vitamin B9 Phase 4,Phase 2,Phase 3,Phase 1
14 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 topoisomerase I inhibitors Phase 4,Phase 2,Phase 1
16 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
18 Folate Phase 4,Phase 2,Phase 3,Phase 1
19 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
20 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
21 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
22 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
23 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
24 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1
25
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
26
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
27
Esomeprazole Approved, Investigational Phase 3 161796-78-7, 119141-88-7 4594 9579578
28
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
29
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 154361-50-9 60953
30
Cetuximab Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 205923-56-4 56842117 2333
31
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
32
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
33
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
34
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
35
Trioxsalen Approved Phase 3,Phase 2 3902-71-4 5585
36
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2 1177-87-3
37
Ranitidine Approved Phase 3 66357-35-5, 66357-59-3 3001055
38
Ondansetron Approved Phase 3 99614-02-5 4595
39
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
40
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
41
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1 180288-69-1 9903
42 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
43 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
45 Proton Pump Inhibitors Phase 3
46 Platelet Aggregation Inhibitors Phase 3,Phase 2
47 Antipyretics Phase 3
48 Analgesics, Non-Narcotic Phase 3,Phase 2,Phase 1
49 Anti-Ulcer Agents Phase 3
50 Gastrointestinal Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 284)
# Name Status NCT ID Phase Drugs
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
3 Combination Chemotherapy in Treating Patients With Esophageal Cancer Unknown status NCT00041262 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil
4 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Unknown status NCT00357682 Phase 3 Esomeprazole;Esomeprazole;Aspirin
5 STRETTA ,Radio Frequency Ablation (RFA) v/s Sham Therapy for the Treatment of Refractory GERD Unknown status NCT02935881 Phase 3
6 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3 chemotherapy;cisplatin;fluorouracil
7 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3 cisplatin;fluorouracil
8 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3 capecitabine;cisplatin
9 Confocal Endomicroscopy for Barrett's Esophagus Completed NCT00487695 Phase 3
10 Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer Completed NCT00047112 Phase 3 cisplatin;fluorouracil
11 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00002631 Phase 3 chemotherapy;cisplatin;fluorouracil
12 Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00003118 Phase 3 cisplatin;fluorouracil
13 Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer Completed NCT00020787 Phase 3 cisplatin;fluorouracil
14 Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer Completed NCT00861094 Phase 2, Phase 3 cisplatin;5-FU;oxaliplatin;Folinic Acid
15 Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Completed NCT01243398 Phase 3
16 Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery Completed NCT01107639 Phase 3 cisplatin;docetaxel
17 Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer Completed NCT00978549 Phase 3 docetaxel;steroid therapy
18 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Completed NCT00052910 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil;leucovorin calcium
19 Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus Recruiting NCT02509286 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
20 NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) Recruiting NCT01726452 Phase 3 Epirubicin;Cisplatin;5 Flourouracil/ Capecitabine;Paclitaxel;Carboplatin
21 Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction Recruiting NCT01523015 Phase 2, Phase 3
22 A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Recruiting NCT03013010 Phase 3 Tegafur-Gimeracil-Oteracil Potassium;Oxaliplatin
23 Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Recruiting NCT02628665 Phase 3 photosensitizer(photofrin)
24 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Active, not recruiting NCT01196390 Phase 3 Carboplatin;Paclitaxel
25 Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer Not yet recruiting NCT03801876 Phase 3 Carboplatin;Paclitaxel
26 Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma Unknown status NCT00964080 Phase 1, Phase 2 MBP-426/Leucovorin/5-FU
27 The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma Unknown status NCT00674167 Phase 2 Docetaxel;Cisplatin;Capecitabine
28 Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach Unknown status NCT00601705 Phase 2 cisplatin;epirubicin hydrochloride;fluorouracil;oxaliplatin
29 Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus Unknown status NCT00903136 Phase 1, Phase 2
30 Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus Unknown status NCT00003326 Phase 2 paclitaxel
31 Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer Unknown status NCT00006472 Phase 2 carboplatin;fluorouracil;paclitaxel
32 Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus Unknown status NCT00005607 Phase 2 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
33 Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer Unknown status NCT00004236 Phase 2 pegylated liposomal doxorubicin hydrochloride
34 Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery Unknown status NCT00005876 Phase 2 rubitecan
35 Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma Completed NCT00220103 Phase 2 epirubicin, capecitabine, cisplatin
36 Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma Completed NCT00583674 Phase 2 AMG 386 placebo;AMG 386 10mg/kg;AMG 386 3mg/kg;Cisplatin;Capecitabine;Cisplatin;Capecitabine;Cisplatin;Capecitabine
37 Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus Completed NCT00259987 Phase 2 Lapatinib (GW572016) oral tablets
38 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction Completed NCT00077545 Phase 2 triapine;cisplatin
39 A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects Completed NCT02096666 Phase 1, Phase 2 AMG 337
40 Phase II Study of Irinotecan and Panitumumab Completed NCT00836277 Phase 2 Panitumumab;Irinotecan
41 Irinotecan in Treating Patients With Esophageal or Stomach Cancer Completed NCT00003748 Phase 2 irinotecan hydrochloride
42 Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia Completed NCT00591123 Phase 2 FOLFOX and Erlotinib
43 Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer Completed NCT00354679 Phase 2 cisplatin;irinotecan hydrochloride
44 Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction Completed NCT00891878 Phase 2 capecitabine;sunitinib malate
45 Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus Completed NCT00066716 Phase 2 carboplatin;celecoxib;paclitaxel
46 Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach Completed NCT00020761 Phase 2 irinotecan hydrochloride;paclitaxel
47 Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach Completed NCT00003237 Phase 2 cisplatin;paclitaxel
48 Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer Completed NCT00985192 Phase 2 everolimus
49 Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Completed NCT00938470 Phase 2 capecitabine;docetaxel;fluorouracil;oxaliplatin
50 Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer Completed NCT00040859 Phase 2 capecitabine;oxaliplatin

Search NIH Clinical Center for Esophagus Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma of esophagus

Genetic Tests for Esophagus Adenocarcinoma

Anatomical Context for Esophagus Adenocarcinoma

MalaCards organs/tissues related to Esophagus Adenocarcinoma:

41
Liver, Bone, Lung, Skin, Colon, Breast, Pancreas

Publications for Esophagus Adenocarcinoma

Articles related to Esophagus Adenocarcinoma:

(show all 19)
# Title Authors Year
1
C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis. ( 27636117 )
2017
2
Preliminary evaluation for Bit1 as a potential biomarker for squamous cell carcinoma and adenocarcinoma of esophagus. ( 28488526 )
2017
3
The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma. ( 28184414 )
2017
4
Epigenetic regulation on the gene expression signature in esophagus adenocarcinoma. ( 28049580 )
2016
5
Four cases of adenocarcinoma of esophagus with co-existing hydatid cyst of liver which caused delayed management of carcinoma esophagus. ( 24869991 )
2015
6
In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma. ( 24708360 )
2014
7
Esophagus adenocarcinoma in a young patient with celiac disease; Is celiac disease a predisposing factor for esophagus adenocarcinoma as well as squamous cell carcinoma? ( 26185881 )
2014
8
Research on the typical miRNA and target genes in squamous cell carcinoma and adenocarcinoma of esophagus cancer with DNA microarray. ( 24519530 )
2014
9
Increase of epidermal growth factor receptor expression in progression of GERD, Barrett, and adenocarcinoma of esophagus. ( 22875307 )
2013
10
Esophagogastric metaplasia relates to nodal metastases in adenocarcinoma of esophagus and cardia. ( 23434259 )
2013
11
Comparative evaluation of serum C-reactive protein (CRP) levels in the different histological subtypes of esophageal cancer (squamous cell carcinoma and adenocarcinoma of esophagus). ( 22467322 )
2012
12
Hedgehog signaling activation in the development of squamous cell carcinoma and adenocarcinoma of esophagus. ( 22509480 )
2012
13
Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. ( 21166737 )
2010
14
Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. ( 17236199 )
2007
15
Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. ( 16985029 )
2006
16
WITHDRAWN: Expression of p53, p63, and p73 isoforms in squamous cell carcinoma and adenocarcinoma of esophagus☆,☆☆ ( 16126170 )
2005
17
Motor neuronopathy associated with adenocarcinoma of esophagus. ( 15129881 )
2004
18
Ultrasound-guided fine-needle aspiration diagnosis of adenocarcinoma of esophagus with signet-ring cell features arising in Barrett's esophagus: a case report. ( 9664184 )
1998
19
Meningeal carcinomatosis in patient with esophagus adenocarcinoma. ( 9105327 )
1997

Variations for Esophagus Adenocarcinoma

Expression for Esophagus Adenocarcinoma

Search GEO for disease gene expression data for Esophagus Adenocarcinoma.

Pathways for Esophagus Adenocarcinoma

Pathways related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.29 CDX2 ERBB2 SMAD4 TP53
2 11.65 PTGS2 SMAD4 TP53
3 11.64 ERBB2 MIR143 MIR145 MIR21 MIR215 PTGS2
4 11.39 ERBB2 SMAD4 TP53
5 10.84 PTGS2 SMAD4 TP53

GO Terms for Esophagus Adenocarcinoma

Biological processes related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.81 MIR21 PTGS2 SMAD4 TP53
2 positive regulation of protein kinase B signaling GO:0051897 9.71 ERBB2 MIR143 MIR21
3 negative regulation of angiogenesis GO:0016525 9.63 MIR143 MIR145 MIR21
4 regulation of ERK1 and ERK2 cascade GO:0070372 9.55 ERBB2 MIR145
5 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.52 MIR143 MIR21
6 regulation of smooth muscle contraction GO:0006940 9.49 MIR143 MIR145
7 cellular sodium ion homeostasis GO:0006883 9.48 ATP12A ATP4A
8 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.43 ATP12A ATP4A
9 cellular potassium ion homeostasis GO:0030007 9.4 ATP12A ATP4A
10 sodium ion export across plasma membrane GO:0036376 9.37 ATP12A ATP4A
11 angiotensin-activated signaling pathway GO:0038166 9.32 MIR143 MIR145
12 aorta smooth muscle tissue morphogenesis GO:0060414 9.26 MIR143 MIR145
13 regulation of phenotypic switching GO:1900239 9.16 MIR143 MIR145
14 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 8.96 MIR143 MIR145
15 negative regulation of cardiac muscle hypertrophy GO:0010614 8.8 MIR145 MIR21 SMAD4

Molecular functions related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen GO:0016702 9.16 CDO1 PTGS2
2 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP12A ATP4A
3 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Esophagus Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....